You just read:

Halozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types

News provided by

Halozyme Therapeutics, Inc.

Nov 10, 2016, 08:30 ET